HideChilds = False
SystemName =
 

Forward-Looking Statements

This website contains forward-looking statements, including statements relating to: business and strategic objectives; growth prospects and potential opportunities for commercial products and pipeline programs; planned geographic expansion; manufacturing, supply and distribution arrangements; relationships with collaborators and other third parties; research and development activities and priorities; anticipated clinical trials and data readouts; business development plans and opportunities; and expected capitalization, revenues, operating margin, cash flows and other financial guidance.  These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “will” and other words and terms of similar meaning. You should not place undue reliance on these statements.

These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including:  Bioverativ’s dependence on revenues from sales of ELOCTATE®* and ALPROLIX®*; failure to compete effectively due to significant product competition in the markets in which Bioverativ operates; product quality or safety concerns, including the occurrence of adverse safety events; product development risks; risks associated with clinical trials; risks relating to actions of regulatory authorities; risks related to reliance on third parties for manufacturing, supply and distribution of Bioverativ’s products and product candidates; difficulties in obtaining and maintaining adequate coverage, pricing and reimbursement for Bioverativ’s products; failure to obtain and maintain adequate protection for intellectual property and other proprietary rights; risks of doing business in international markets; risks associated with current and potential future healthcare reforms; failure to identify and execute on business development and research and development opportunities;  Bioverativ’s dependence on relationships with collaborators and other third parties for revenue and other aspects of its business; loss of key employees or inability to attract and retain key personnel; disruptions to, or other adverse impact on Bioverativ’s relationships with its customers and other business partners; failure to comply with legal and regulatory requirements affecting Bioverativ’s business; the impact of global economic conditions; fluctuations in foreign exchange and interest rates; changes in the law concerning the taxation of income; risks relating to technology failures or breaches; the outcome of any significant legal proceedings; the adequacy of the Bioverativ’s cash flows from operations; Bioverativ’s lack of operating history as a standalone business; risks relating to the separation from Biogen, including, among others, failure to achieve the anticipated benefits from the separation, reliance on Biogen and other third parties to provide certain services post-separation, restrictions to preserve the tax-free treatment of the separation that may impact Bioverativ’s strategic and operating flexibility, and Bioverativ’s ability to satisfy liabilities and potential indemnification obligations in connection with the separation; and other risks and uncertainties described in the Risk Factors section of Bioverativ’s Registration Statement on Form 10 and other filings with the Securities and Exchange Commission. 

These statements are based on Bioverativ’s current beliefs and expectations and speak only as of the date of this website.  Bioverativ does not undertake any obligation to publicly update any forward-looking statements.

Note Regarding Trademarks.  Bioverativ owns or has rights to use the trademarks, service marks and trade names that it uses in conjunction with the operation of its business.  Some of the trademarks that appear in this website include:  ALPROLIX® and ELOCTATE®, which may be registered or trademarked in the U.S. and other jurisdictions.  Each trademark, trade name or service mark of any other company appearing in this website is, to Bioverativ’s knowledge, owned by such other company.  

* Bioverativ was created as a spin-off from Biogen’s hemophilia business and separated from Biogen effective February 1, 2017. Bioverativ is an independent, publicly-traded company, headquartered in Waltham, Massachusetts. During a temporary transition period, which includes time to allow Bioverativ to establish or transfer certain licenses related to ELOCTATE and ALPROLIX, each of Bioverativ and Biogen will have a relationship to the products.  Contact us with any questions.